Free Trial

Novartis Q3 2024 Earnings Report

Novartis logo
$97.11 +0.34 (+0.35%)
(As of 12/20/2024 04:33 PM ET)

Novartis EPS Results

Actual EPS
$2.06
Consensus EPS
$1.94
Beat/Miss
Beat by +$0.12
One Year Ago EPS
$1.74

Novartis Revenue Results

Actual Revenue
$12.82 billion
Expected Revenue
$12.62 billion
Beat/Miss
Beat by +$205.14 million
YoY Revenue Growth
N/A

Novartis Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Novartis Earnings Headlines

Brokerages Set Novartis AG (NYSE:NVS) Target Price at $121.50
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
BioAge Labs announces multi-year collaboration with Novartis
See More Novartis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novartis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novartis and other key companies, straight to your email.

About Novartis

Novartis (NYSE:NVS) engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

View Novartis Profile

More Earnings Resources from MarketBeat

Upcoming Earnings